Key result
In patients with coronary artery disease, type 2 diabetes was associated with significantly higher TRAP-6-inducible P-selectin expression compared to nondiabetic patients (median 69.5 vs 46.3 MFI, p=0.03).
Why the study?
Does diabetes enhance platelet activation in patients with symptomatic coronary artery disease compared to other manifestations of atherosclerosis?
Population
367 individuals, comprising 317 patients undergoing percutaneous intervention with endovascular stent…
Design
Cross-sectional
Authors
Loading...
May indicate diabetes-specific platelet effects in CAD; hypothesis-generating and should not yet change practice.
Cross-Sectional (n=367)
No
Does diabetes enhance platelet activation in patients with symptomatic coronary artery disease compared to other manifestations of atherosclerosis?
Absolute Event Rate: 69.5% vs 46.3%
p-value: p=0.03
Diabetes significantly enhances platelet activation in patients with symptomatic coronary artery disease, but does not further increase the already high platelet reactivity seen in peripheral or cerebrovascular disease.
Gremmel et al. (2013) conducted a cross-sectional in Symptomatic atherosclerotic disease (CAD, PAD/CVD) (n=367). Type 2 diabetes vs. Nondiabetic patients was evaluated on TRAP-6-inducible P-selectin expression (MFI) in patients with coronary artery disease (p=0.03). In patients with coronary artery disease, type 2 diabetes was associated with significantly higher TRAP-6-inducible P-selectin expression compared to nondiabetic patients (median 69.5 vs 46.3 MFI, p=0.03).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: